Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept and High Dose IL-2 in Advanced Melanoma
NCT01258855Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2011
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 5 years. Started Jan 2011; status: completed.
02
Drugs
aflibercept
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01258855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01258855.